Rongchang Biotechnology: The indication for the use of vedolizumab as first-line treatment for HER2-expressing urothelial carcinoma has been approved.

Rongchang Biotech Announcement, Recently, the company has received the "Drug Registration Certificate" issued by the National Medical Products Administration, and the application for the new indication of Vedeci's Trimetrexate Combined with Tecrepin's Trimetrexate for the treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma has been approved. This is the fifth indication approved for Vedeci's Trimetrexate in China.